Fundamental Analysis of CELLECTAR BIOSCIENCES INC(NASDAQ:CLRB) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to CLRB. CLRB was compared to 565 industry peers in the Biotechnology industry. While CLRB seems to be doing ok healthwise, there are quite some concerns on its profitability. CLRB is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

CLRB had negative earnings in the past year.

In the past year CLRB has reported a negative cash flow from operations.

CLRB had negative earnings in each of the past 5 years.

CLRB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

CLRB has a worse Return On Assets (-133.20%) than 83.45% of its industry peers.

CLRB has a worse Return On Equity (-300.20%) than 74.73% of its industry peers.

		Industry Rank	Sector Rank
ROA	-133.2%
ROE	-300.2%
ROIC	N/A

ROA(3y)-170.62%

ROA(5y)-130.52%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CLRB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for CLRB has been increased compared to 1 year ago.

CLRB has more shares outstanding than it did 5 years ago.

CLRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

CLRB has an Altman-Z score of -12.98. This is a bad value and indicates that CLRB is not financially healthy and even has some risk of bankruptcy.

CLRB has a Altman-Z score of -12.98. This is in the lower half of the industry: CLRB underperforms 79.54% of its industry peers.

CLRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-12.98

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 1.77 indicates that CLRB should not have too much problems paying its short term obligations.

Looking at the Current ratio, with a value of 1.77, CLRB is doing worse than 78.83% of the companies in the same industry.

A Quick Ratio of 1.77 indicates that CLRB should not have too much problems paying its short term obligations.

CLRB has a worse Quick ratio (1.77) than 77.40% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.77
Quick Ratio	1.77

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.98% over the past year.

EPS 1Y (TTM)37.98%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%51.81%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.54% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y44.47%

EPS Next 2Y32.33%

EPS Next 3Y19.18%

EPS Next 5Y18.54%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CLRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLRB. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CLRB's earnings are expected to grow with 19.18% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y32.33%

EPS Next 3Y19.18%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CLRB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CELLECTAR BIOSCIENCES INC

NASDAQ:CLRB (12/23/2024, 10:52:33 AM)

0.2423

+0.01 (+5.35%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-18 2024-11-18/bmo

Earnings (Next)N/A N/A

Inst Owners28.14%

Inst Owner Change21.04%

Ins Owners3.08%

Ins Owner Change0%

Market Cap10.00M

Analysts86

Price Target13.52 (5479.86%)

Short Float %3.46%

Short Ratio0.77

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)43.1%

Min EPS beat(2)-5.28%

Max EPS beat(2)91.47%

EPS beat(4)1

Avg EPS beat(4)13.12%

Min EPS beat(4)-28.79%

Max EPS beat(4)91.47%

EPS beat(8)3

Avg EPS beat(8)6.13%

EPS beat(12)5

Avg EPS beat(12)3.83%

EPS beat(16)8

Avg EPS beat(16)5.71%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-14.52%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0.7%

EPS NY rev (1m)9.89%

EPS NY rev (3m)9.89%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.6
P/tB	0.6
EV/EBITDA	N/A

EPS(TTM)-1.78

EYN/A

EPS(NY)-0.73

Fwd EYN/A

FCF(TTM)-1.13

FCFYN/A

OCF(TTM)-1.12

OCFYN/A

SpS0

BVpS0.4

TBVpS0.4

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-133.2%
ROE	-300.2%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-170.62%

ROA(5y)-130.52%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	103.89%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.77
Quick Ratio	1.77
Altman-Z	-12.98

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)231.93%

Cap/Depr(5y)150.81%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)37.98%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%51.81%

EPS Next Y44.47%

EPS Next 2Y32.33%

EPS Next 3Y19.18%

EPS Next 5Y18.54%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-52.47%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-106.44%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-107.29%

OCF growth 3YN/A

OCF growth 5YN/A

CELLECTAR BIOSCIENCES INC (CLRB)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens